Emily Menendez

GU Oncology Now

The use of 68Ga-PSMA positron emission tomography (PET) for prostate cancer (PCa) restaging is recommended for patients who still experience prostate-specific antigen (PSA) persistence or biochemical recurrence (BCR) after receiving radical prostatectomy (RP). However, the effect that metastasis-directed therapy (MDT) has on progression-free survival (PFS) is not yet fully understood. <a href="https://www.auajournals.org/doi/10.1097/JU.0000000000003226.06" target="_blank" rel="noopener">A study</a> presented at the American Urological Association 2023 Annual Meeting sought to determine if MDT may affect PFS in patients with positive prostate-specific membrane antigen (PSMA) PET.A group of 361 patients who were evaluated with 68Ga-PSMA PET/computed tomography (CT) for BCR after RP between 2016 and 2022 were retrospectively identified. Each patient was placed in a negative (n=135) or positive (n=226) group based on PSMA PET results. In the positive group, MDT consisted of stereotactic ablative radiation therapy on positive spots. Adverse pathological responses (eg, Gleason Grade Group 4-5 with &ge;pT3a stage and/or lymph node invasion) and salvage treatments were also compared between the 2 groups.Clinical recurrence (CR) was defined as any new metastases detected at imaging after first PSMA PET. Cox regression analyses were used to measure the impact of a positive PSMA PET and its interaction with MDT on CR after adjusting for PSA level at PSMA PET. Multivariable Cox-derived Kaplan-Meier (KM) analyses depicted the time from the first PSMA PET to CR.Among the total number of patients with a positive scan, 113 (31%) patients received MDT. The median follow-up was 30 months after PSMA PET. The 3-year CR-free survival rates for negative and positive PSMA PET scans since BCR were 72% and 42%, respectively. At Cox analyses, a positive PSMA PET scan was associated with a 2-fold higher risk of PFS during follow-up compared with a negative PSMA PET (hazard ratio [HR], 2.09; P=.003) after adjusting for confounders.When testing interaction with the use of MDT in patients with positive PSMA PET, patients with positive PSMA PET not receiving MDT had a higher risk of CR (HR, 2.66; P&lt;.001). This risk was higher but with lesser magnitude in patients with positive PSMA PET (HR, 1.74; P=.04) receiving MDT compared with patients with negative PSMA PET. At the time of Cox-derived KM analyses, the 3-year CR-free survival rate was 73% in patients with negative PSMA PET, 51% in patients with positive PSMA PET with MDT, and 29% in patients with positive PSMA PET without MDT.A negative PSMA PET scan is seen as a protective factor for further metastases during follow-up. In patients with positive spots, MDT significantly improved PFS, but it is not comparable to the protective effect of a negative PSMA PET.

68Ga-PSMA PET/CT and Metastasis-Directed Therapy in Prostate Cancer

AUA 2023

The effect that MDT has on PFS is not yet fully understood. A study presented at AUA 2023 sought to determine if MDT may affect PFS in patients with PSMA PET.

68Ga-PSMA PET/CT and Metastasis-Directed Therapy

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe